Compare Abeona Therapeutics Inc (ABEO) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares UltraPro S&P500 — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while ProShares UltraPro S&P500 trades at $154.05. Which is the better fit depends on your goals.
| ABEO | UPRO | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.45 | $155.10 |
52-Week Low | $4.17 | $89.29 |
Enterprise Value | $276.10M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
